Showing results (361-370 of 401) with videos related to
Sort By:
Pageof 41
Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.Breast Cancer Research and Treatment|February 3, 2007
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)Jennifer M Specht, Stephen L Tam, Brenda F Kurland, et al.Journal of the American Chemical Society|June 13, 2025
Isomerization of Poly(ethylene glycol): A Strategy for the Evasion of Anti-PEG Antibody RecognitionPhilip Dreier, Rebecca Matthes, Fabian Fuß, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden, Charles M Haskell, Stephanie J Green, et al.Research Square|February 5, 2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trialsMark Muzi, Lanell M Peterson, Jennifer M Specht, et al.EJNMMI Research|March 27, 2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trialsMark Muzi, Lanell M Peterson, Jennifer M Specht, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2018
Test-Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local NetworkBrenda F Kurland, Lanell M Peterson, Andrew T Shields, et al.Molecular Imaging and Biology|October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.EJNMMI Research|June 27, 2012
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patientsBrenda F Kurland, Vijayakrishna K Gadi, Jennifer M Specht, et al.Molecular Imaging and Biology|October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.Pageof 41